Opinion

Video

A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment

Adiel Smith, MD, FASRS, presents the case of a patient with neovascular age-related macular degeneration (nAMD) with treatment-resistant pigment epithelium detachment, and the panel offers clinical insights on treatment decisions.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) AGS 2025: Long-term efficacy and safety of standalone and phaco ELT with Marc Toeteberg-Harms, MD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Related Content
(Image credit: AdobeStock/©KayExam/peopleimages.com)
March 10th 2025

A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

4DMT enrolls first patient in phase 3 4FRONT-1 evaluating 4D-150 for the treatment of wet AMD
March 10th 2025

4DMT enrolls first patient in phase 3 4FRONT-1 evaluating 4D-150 for the treatment of wet AMD

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

PER launches Retina Resource, an anti-VEGF education and information tool
March 8th 2025

PER launches Retina Resource, an anti-VEGF education and information tool

Luxa Biotechnology presents data from phase 1/2a clinical trial evaluating RPESC-RPE-4W
March 7th 2025

Luxa Biotechnology presents data from phase 1/2a clinical trial evaluating RPESC-RPE-4W

© 2025 MJH Life Sciences

All rights reserved.